Cardiovascular Disease Doctors in Guilford, CT Accepting Medicare

4 Cardiovascular Disease doctors found. Showing 1 - 4

Jude F Clancy, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Goose Ln, Yale New Haven Shoreline Medical Center Ste 2400, Guilford, CT 06437 Phone: 203-458-2097    Fax: 203-458-1592

L Veronica Lee, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 111 Goose Ln Ste 2400, Guilford, CT 06437 Phone: 203-458-2097    Fax: 203-458-1592

Albert J Sinusas, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Goose Ln, Yale-new Haven Shoreline Medical, Suite 2400, Guilford, CT 06437 Phone: 203-458-2097    Fax: 203-458-1592

Daniel M Greif, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Goose Ln, Guilford, CT 06437 Phone: 203-458-2097

News Archive

Study identifies the source of inherent noise in HIV gene expression

New research identifies a molecular mechanism that the human immunodeficiency virus (HIV) appears to utilize for generating random fluctuations called "noise" in its gene expression.

Uninsured populations to receive health care coverage through grants from HHS

HHS Secretary Kathleen Sebelius has announced $70.9 million in grants to 13 states to support the expansion of health care coverage for their uninsured populations.

Efficacy of neurofeedback in treating ADD/ADHD

On January 22, the Potomac Institute for Policy Studies will present a guest lecture by Don DuRousseau, founder and CEO of Human Bionics LLC, a neurotechnology company specializing in brain-computer interface (BCI) systems. Mr. DuRousseau will explore the use of neurotechnology techniques, including the increasingly popular neurofeedback, as a treatment for ADD/ADHD.

Ranbaxy receives tentative approval to manufacture Valganciclovir hydrochloride tablets

Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS - MAT: March 2008).

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

Read more Medical News

› Verified 7 days ago